TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02672839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGD-6972 Solution
Description: 15 mg of LGD-6972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGD-6972 Solution
Description: 15 mg of LGD-6972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGD-6972 Capsules
Description: 15 mg LGD-6972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGD-6972 Capsules
Description: 15 mg LGD-6972
Study: NCT01757457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intracoronary administration of an abciximab bolus during primary PCI
Description: Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous administration of an abciximab bolus during primary PCI
Description: Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI
Study: NCT03427840

Intervention type: PROCEDURE
Intervention: Procedure/Surgery: superior hypogastric block
Description: superior hypogastric blockade during surgery
Study: NCT02333045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada qd
Description: Truvada 1 tablet PO daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc 300 qd
Description: Maraviroc 300 mg PO daily for 7 days
Study: NCT01751646

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 50,000 IU
Description: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 placebo
Description: Group B: Vitamin D3 placebo orally every four weeks by DOT
Study: NCT03224533

Intervention type: DIAGNOSTIC_TEST
Intervention: Diabetes Outcome
Description: based on self report definition, fasting plasma glucose, and hemoglobin A1c

Intervention type: DIAGNOSTIC_TEST
Intervention: Diabetes Outcome
Description: based on self report definition, fasting plasma glucose, and hemoglobin A1c
Study: NCT02727725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traminer MRI Sequence
Description: The Traminer MRI sequence will be added to the standard IR Turbo-Flash sequence and last 2-5 minutes.
Study: NCT00945191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-1008
Description: CS-1008 intravenous (IV) infusion 10 mg/kg on Day 1 of Cycle 1 and 8 mg/kg once every 3 weeks (1 cycle) for Cycle 2-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m\^2 IV infusion once every 3 weeks (1 cycle) for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (target area under the concentration versus time curve of 6.0 mg/mL/min using the Calvert Formula) IV infusion once every 3 weeks (1 cycle) for 6 cycles
Study: NCT02405312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: advance care planning
Description: patient and family meeting with dialysis social worker and nephrologist with discussion of advance care planning and hospice resources
Study: NCT02093026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive rituximab 1 gram IV on Days 1 and 15 of each course of retreatment.
Study: NCT03035643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMDS
Description: The device will be implanted during an already planned surgical intervention for aortic dissection repair. The participant will be observed and data gathered during the surgery and routine standard of care follow up visits.
Study: NCT02093026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants will receive methotrexate 10-25 mg/week orally or parenterally.
Study: NCT05527639

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: strength training program
Description: 12-weeks of strength training consisting of warm ups, dead-lifts, squats and cool down exercises

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: strength training program
Description: 12-weeks of strength training consisting of warm ups, dead-lifts, squats and cool down exercises
Study: NCT02093026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Participants will receive methylprednisolone 100 mg IV 30 minutes prior to each rituximab infusion.
Study: NCT00063999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study: NCT03940170

Intervention type: DEVICE
Intervention: vistacam proof
Description: Light fluorescence device

Intervention type: DEVICE
Intervention: vistacam proof
Description: Light fluorescence device

Intervention type: OTHER
Intervention: ICDASII
Description: visual examination

Intervention type: OTHER
Intervention: ICDASII
Description: visual examination

Intervention type: PROCEDURE
Intervention: fissurotomy
Description: histological validation
Study: NCT00063999

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Given SC

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02021461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESL Banana taste
Description: oral suspension with Banana flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESL Grape taste
Description: oral suspension with Grape flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
Study: NCT00063999

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT02093026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Participants will receive folic acid \>= 5 mg/week or equivalent.
Study: NCT00063999

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: Given SC
Study: NCT04281953

Intervention type: DIAGNOSTIC_TEST
Intervention: High frequency audiometry
Description: Simple hearing test

Intervention type: OTHER
Intervention: Short-Form 36-Item Questionnaire (SF-36)
Description: Questionnaire on quality of life (Short Form 36 Item- SF-36)

Intervention type: OTHER
Intervention: Hearing handicap inventory for adults/elderly (HHIA/HHIE)
Description: Questionnaire on Hearing loss (Hearing handicap inventory for adults/elderly- HHIA/HHIE)

Intervention type: OTHER
Intervention: Tinnitus handicap inventory (THI)
Description: Questionnaire on Tinnitus (Tinnitus Handicap Inventory)
Study: NCT02021461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESL Tutti-Frutti taste
Description: oral suspension with Tutti-Frutti flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
Study: NCT02067312

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Thai massage
Study: NCT01112683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: The drug dosage will follow memantine's standard titration schedule (i.e., 5 mg/d week one, 5 mg/BID week two, 5 \& 10 mg/d divided dose week three, 10mg/BID week four).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: These are identically-looking pills to those in the Memantine Arm.
Study: NCT01686802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Study: NCT03363425

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Iv
Description: Lidocaine Iv

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine iv

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: placebo
Study: NCT01732653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TT+VR
Description: subjects will be walking on a treadmill while negotiating virtual obstacles provided by a computer simulation. The virtual environment will consist of obstacles, different pathways, narrow corridors and distracters, requiring modulations of step amplitude in two planes (i.e., height and width) coordinated with walking behaviour. The speed, orientation, size, frequency of appearance and shape of the targets will be manipulated according to individual needs following a standardized protocol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TT alone
Description: The participants will walk on the treadmill, their gait speed over-ground will be measured at the beginning of each week of training. Progression will include increasing the duration of each of the walking bouts and increasing walking speed.
Study: NCT03790631

Intervention type: OTHER
Intervention: The study is observational.
Description: The study is observational.

Intervention type: OTHER
Intervention: The study is observational.
Description: The study is observational.

Intervention type: OTHER
Intervention: The study is observational.
Description: The study is observational.

Intervention type: OTHER
Intervention: The study is observational.
Description: The study is observational.
Study: NCT01620359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate MRgFUS
Description: 100% ablation of an up-to-2-cm breast cancer visible on an contrast-enhanced MRI with 5-10 mm margins around the primary tumor
Study: NCT02067312

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thai massage
Study: NCT04537637

Intervention type: DRUG
Intervention: Oral Semaglutide
Description: Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
Study: NCT03790631

Intervention type: OTHER
Intervention: The study is observational.
Description: The study is observational.

Intervention type: OTHER
Intervention: The study is observational.
Description: The study is observational.

Intervention type: OTHER
Intervention: The study is observational.
Description: The study is observational.
Study: NCT01031095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: coronary intervention
Description: elective coronary intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: coronary intervention
Description: elective coronary intervention
Study: NCT00797342

Intervention type: DRUG
Group type: OTHER
Intervention: PF-04629991
Description: Oral; Sequential single dose escalation; three fourteen-day treatment periods per subject in the first cohort; randomized sequence of treatments (one placebo and two PF-04629991 doses)

Intervention type: DRUG
Group type: OTHER
Intervention: PF-04629991
Description: Oral; Sequential single dose escalation; three fourteen-day treatment periods per subject in the second cohort; randomized sequence of treatments (one placebo and two PF-04629991 doses)
Study: NCT00077233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin
Description: IV
Study: NCT00797342

Intervention type: DRUG
Group type: OTHER
Intervention: PF-04629991
Description: Oral; sequential single dose escalation; three fourteen-day treatment periods per subject in the third cohort; randomized assignment to treatment (placebo or PF-04629991)
Study: NCT04264052

Intervention type: DIAGNOSTIC_TEST
Intervention: CBE & MRI
Description: The diagnostic tests will be consisted by two visits.~In the first visit participants will undergo a medical history assessment and they will complete questionnaires related to the lung function (MRC Dyspnoea score, Dyspnoea-12 questionnaire, and Visual Analogue Scale). A spirometry will be performed to assess the lung function. Bronchoscopy will be performed at rest in a semi-supine position (on a reclined bed) and then during exercise on a treadmill.~In the second visit, spirometry and questionnaires will be performed prior to resting and during exercise measurements on a magnetic resonance imaging (MRI) scan.~Rest: Structural imaging of the neck and chest will be performed followed by dynamic imaging of the airways during several inspiratory and expiratory manoeuvres. No IV contrast media will be used.
Study: NCT01649843

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POEM
Description: Peroral endoscopic myotomy (POEM) has recently been described as a new minimally invasive endoscopic myotomy technique intending a permanent cure from primary achalasia in some centers.
Study: NCT02270437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine, fentanyl, adrenaline
Description: The patients in the cocktail analgesia group received an injection of 200mg ropivacaine, 100ug fentanyl, and 0.25mg adrenaline into knee collateral ligaments, posterior aspect of the capsule, quadriceps tendon, patellar tendon, fat pad, periosteum, and synovium, along with PCIA morphine postoperatively.
Study: NCT01967784

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza Vaccine (split virion, inactivated)
Description: 0.5 mL, Intramuscular
Study: NCT02895009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: experimental group
Description: Participants allocated to the experimental group will receive a short term postoperative puncture site compression via TR Band. TR Band deflation is commenced at the 1st hour and completed at the 3rd hour, and the TR Band is removed at the 12th hour.

Intervention type: DEVICE
Group type: OTHER
Intervention: control group
Description: Participants allocated to the control group will receive a routine long term postoperative puncture site compression via TR Band. TR Band deflation is commenced at the 2nd hour and completed at the 6th hour, and the TR Band is removed at the 24th hour.
Study: NCT04033523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT
Description: The HF group performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 3 days/week for 12 weeks
Study: NCT01009281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Study: NCT00876798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixivaptan
Description: Capsules, 25mg lixivaptan or matching placebo once daily. Study medication can be titrated up to 50mg or 100mg once daily. Acceptable dosages are once daily administration of 25mg, 50mg, or 100mg as a single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule. Subjects will be randomized (3:1) on an outpatient basis to 25 mg lixivaptan or matching placebo, once daily.
Study: NCT01650675

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WIDUS computer-delivered, indirect brief intervention
Description: A single 20-minute interactive computer-delivered intervention designed to promote motivation to change drug use and risky sexual behavior, if any, without presuming those risks to be specifically present.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition time control/placebo intervention
Description: This time-control intervention, designed in part to help promote RA blinding as to participant condition, focuses on proper infant nutrition using a computer-delivered, interactive format and videos.
Study: NCT03914300

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study: NCT01685346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: biofeedback-mediated stress management (BFSM)
Description: Therapist and study assistant meet with patient, attach sensors, record physiologic variables and train the patient in relaxation techniques including deep breathing, guided imagery, progressive muscle relaxation, autogenics. Patient is given a handheld thermometer to take home and practice self-regulation between visits, along with a recording sheet to indicate how often practice occurs.
Study: NCT03348787

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral and Cognitive Therapies
Description: Group intervention of 6 weekly sessions of one hour and 30 minutes based on the psychoeducational therapeutic principles and CBT type 3 wave Accept Voices applied to HAV
Study: NCT04738929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extra virgin coconut oil or extra virgin olive oil
Description: Subjects consumed standard breakfast meals containing extra virgin coconut oil or extra virgin olive oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extra virgin coconut oil or extra virgin olive oil
Description: Subjects consumed standard breakfast meals containing extra virgin coconut oil or extra virgin olive oil
Study: NCT01299701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA404
Description: (5,6-dimethylxanthenone-4-acetic acid) DMXAA or DXAA
Study: NCT00077233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: IV
Study: NCT00476047

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tositumomab and Iodine I 131 Tositumomab
Description: Give IV
Study: NCT02203084

Intervention type: OTHER
Intervention: Social Determinants Questionnaire
Description: The questionnaire contains a general background information section common to all medical conditions. It then contains separate sections with medical condition specific questions.
Study: NCT01056380

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Tablet, 500 mg with food twice daily for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, twice daily with food for 5 days
Study: NCT00644644

Intervention type: OTHER
Intervention: Rapid Response Team (NTX wireless monitoring system)
Description: If the subject is experiencing a life threatening change in their vital signs, the Rapid Response Team will be initiated per VUMC protocol.
Study: NCT00077233

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: IV
Study: NCT00731029

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thiomersal free trivalent influenza split vaccine 2002/2003
Description: Single dose, intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thiomersal free trivalent influenza split vaccine 2002/2003
Description: Single dose, intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2002/2003
Description: Single dose, intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2002/2003
Description: Single dose, intramuscular injection
Study: NCT00847717

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective neck dissection
Description: Level IIb preserving neck dissection

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional Neck dissection
Description: Conventional neck dissection (MRND type III or Supraomohyoid)
Study: NCT02641899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA 650 20/60 mcg/day
Description: ITCA 650 osmotic mini pump delivering exenatide 20 mcg/day for 14 days, followed by ITCA 650 osmotic mini pump delivering exenatide 60 mcg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Oral acetaminophen 1000 mg on Day 1 and Day 27
Study: NCT02054871

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPC
Description: A standard, CE-approved tourniquet cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure \>185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 3 ischaemia-reperfusion cycles. Additional, blood and urine samples will be collected on Day 1, Day 2 and Day 3 post procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPC
Description: A standard, CE-approved tourniquet cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure \>185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 3 ischaemia-reperfusion cycles. Additional, blood and urine samples will be collected on Day 1, Day 2 and Day 3 post procedure.
Study: NCT01733927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid testing for HIV
Description: The research team members were trained and certified in administering the OQA testing through the AIDS International Consortium in Philadelphia (WHCI), USA. During the recruitment process, participants were informed about the nature of the test, the length of time for results, and what procedures would be involved in self-administering the OQA test. After providing informed consent, including the release of information for research use, participants demonstrated their ability to properly take an OQA sample using a popsicle stick as a proxy for the testing device.
Study: NCT04080687

Intervention type: DEVICE
Intervention: Ankle-foot orthosis
Description: Ankle-foot orthosis of any type (unilateral or bilateral, standard or carbon fiber, for support or correction)

Intervention type: DEVICE
Intervention: Ankle-foot orthosis
Description: Ankle-foot orthosis of any type (unilateral or bilateral, standard or carbon fiber, for support or correction)